Abstract
Biosimilars of infliximab (CT-P13) are currently approved and available for the same indications as for the originator. Some concerns about safety and immunogenicity have risen in the past because of lack of data in IBD. Since 2015, several cohort studies have been conducted in IBD showing that CT-P13 has comparable safety and efficacy profile to the originator, both in adult and pediatric population, either in naïve patients or even in those who switched from the originator to CT-P13. This review aims to analyze the current literature data in order to define a clear patient profile, to identify those IBD patients who would benefit the most from the use of CT-P13.
Keywords: Infliximab, biosimilar, CT-P13, inflammatory bowel disease, Crohn’s disease, ulcerative colitis.
[1]
Peyrin-Biroulet, L.; Deltenre, P.; de Suray, N.; Branche, J.; Sandborn, W.J.; Colombel, J.F. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin. Gastroenterol. Hepatol., 2008, 6(6), 644-653.
[2]
Danese, S.; Fiorino, G.; Peyrin-Biroulet, L.; Lucenteforte, E.; Virgili, G.; Moja, L.; Bonovas, S. Biological agents for moderately to severely active ulcerative colitis: a systematic review and network meta-analysis. Ann. Intern. Med., 2014, 160(10), 704-711.
[3]
Tracey, D.; Klareskog, L.; Sasso, E.H.; Salfeld, J.G.; Tak, P.P. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol. Ther., 2008, 117(2), 244-279.
[4]
European Medicine Agency Remicade. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000240/human_med_001023.jsp&mid=WC0b01ac058001d124 2016.
[5]
Blackstone, E.A.; Joseph, P.F. The economics of biosimilars. Am. Health Drug Benefits, 2013, 6(8), 469-478.
[6]
European Medicines Agency Inflectra. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002778/smops/Positive/human_ smop_000531.jsp&mid=WC0b01ac058001d127
[7]
European Medicines Agency Remsima. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002576/smops/Positive/human_ smop_000532.jsp&mid=WC0b01ac058001d127
[8]
Fiorino, G.; Girolomoni, G.; Lapadula, G.; Orlando, A.; Danese, S.; Olivieri, I. The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun. Rev., 2014, 13(7), 751-755.
[9]
Danese, S.; Gomollon, F. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD). J. Crohn’s Colitis, 2013, 7(7), 586-589.
[10]
Park, W.; Hrycaj, P.; Jeka, S.; Kovalenko, V.; Lysenko, G.; Miranda, P.; Mikazane, H.; Gutierrez-Ureña, S.; Lim, M.; Lee, Y.A.; Lee, S.J.; Kim, H.; Yoo, D.H.; Braun, J. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis., 2013, 72(10), 1605-1612.
[11]
Yoo, D.H.; Hrycaj, P.; Miranda, P.; Ramiterre, E.; Piotrowski, M.; Shevchuk, S.; Kovalenko, V.; Prodanovic, N.; Abello-Banfi, M.; Gutierrez-Ureña, S.; Morales-Olazabal, L.; Tee, M.; Jimenez, R.; Zamani, O.; Lee, S.J.; Kim, H.; Park, W.; Müller-Ladner, U. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis., 2013, 72(10), 1613-1620.
[12]
Park, W.; Yoo, D.H.; Jaworski, J.; Brzezicki, J.; Gnylorybov, A.; Kadinov, V.; Sariego, I.G.; Abud-Mendoza, C.; Escalante, W.J.; Kang, S.W.; Andersone, D.; Blanco, F.; Hong, S.S.; Lee, S.H.; Braun, J. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res. Ther., 2016, 18, 25.
[13]
Yoo, D.H.; Racewicz, A.; Brzezicki, J.; Yatsyshyn, R.; Arteaga, E.T.; Baranauskaite, A.; Abud-Mendoza, C.; Navarra, S.; Kadinov, V.; Sariego, I.G.; Hong, S.S.; Lee, S.Y.; Park, W. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res. Ther., 2016, 18, 82.
[14]
Park, W.; Yoo, D.H.; Miranda, P.; Brzosko, M.; Wiland, P.; Gutierrez-Ureña, S.; Mikazane, H.; Lee, Y.A.; Smiyan, S.; Lim, M.J.; Kadinov, V.; Abud-Mendoza, C.; Kim, H.; Lee, S.J.; Bae, Y.; Kim, S.; Braun, J. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann. Rheum. Dis., 2017, 76(2), 346-354.
[15]
Yoo, D.H.; Prodanovic, N.; Jaworski, J.; Miranda, P.; Ramiterre, E.; Lanzon, A.; Baranauskaite, A.; Wiland, P.; Abud-Mendoza, C.; Oparanov, B.; Smiyan, S.; Kim, H.; Lee, S.J.; Kim, S.; Park, W. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann. Rheum. Dis., 2017, 76(2), 355-363.
[16]
Arguelles-Arias, F.; Barreiro-de-Acosta, M.; Carballo, F.; Hinojosa, J.; Tejerina, T. Joint position statement by Spanish Society of Gastroenterology and Spanish Society of Pharmacology on biosimilar therapy for inflammatory bowel disease. Rev. Esp. Enferm. Dig., 2013, 105(1), 37-43.
[17]
Annese, V.; Vecchi, M. Use of biosimilars in inflammatory bowel disease: Statements of the Italian group for inflammatory bowel disease. Dig. Liver Dis., 2014, 46(11), 963-968.
[18]
Danese, S.; Fiorino, G.; Michetti, P. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn’s and Colitis Organization. J. Crohn’s Colitis, 2014, 8(11), 1548-1550.
[19]
Jorgensen, K.K.; Olsen, I.C.; Goll, G.L.; Lorentzen, M.; Bolstad, N.; Haavardsholm, E.A.; Lundin, K.E.A.; Mork, C.; Jahnsen, J.; Kvien, T.K. Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet (London, England), 2017, 389(10086), 2304-2316.
[20]
Gecse, K.B.; Lovász, B.D.; Farkas, K.; Banai, J.; Bene, L.; Gasztonyi, B.; Golovics, P.A.; Kristóf, T.; Lakatos, L.; Csontos, A.A.; Juhász, M.; Nagy, F.; Palatka, K.; Papp, M.; Patai, Á.; Lakner, L.; Salamon, Á.; Szamosi, T.; Szepes, Z.; Tóth, G.T.; Vincze, Á.; Szalay, B.; Molnár, T.; Lakatos, P.L. Efficacy and safety of the biosimilar infliximab CT-P13 treatment in inflammatory bowel diseases: A prospective, multicentre, nationwide cohort. J. Crohn’s Colitis, 2016, 10(2), 133-140.
[21]
Duron, C.; Goutte, M.; Pereira, B.; Bommelaer, G.; Buisson, A. Factors influencing acute infusion reactions in inflammatory bowel disease patients treated with infliximab in the era of scheduled maintenance therapy. Eur. J. Gastroenterol. Hepatol., 2015, 27(6), 705-711.
[22]
Farkas, K.; Rutka, M.; Bálint, A.; Nagy, F.; Bor, R.; Milassin, Á.; Szepes, Z.; Molnár, T. Efficacy of the new infliximab biosimilar CT-P13 induction therapy in Crohn’s disease and ulcerative colitis - experiences from a single center. Expert Opin. Biol. Ther., 2015, 15(9), 1257-1262.
[23]
Farkas, K.; Rutka, M.; Golovics, P.A.; Végh, Z.; Lovász, B.D.; Nyári, T.; Gecse, K.B.; Kolar, M.; Bortlik, M.; Duricova, D.; Machkova, N.; Hruba, V.; Lukas, M.; Mitrova, K.; Malickova, K.; Bálint, A.; Nagy, F.; Bor, R.; Milassin, Á.; Szepes, Z.; Palatka, K.; Lakatos, P.L.; Lukas, M.; Molnár, T. Efficacy of infliximab biosimilar CT-P13 induction therapy on mucosal healing in ulcerative colitis. J. Crohn’s Colitis, 2016, 10(11), 1273-1278.
[24]
Keil, R.; Wasserbauer, M.; Zádorová, Z.; Hajer, J.; Drastich, P.; Wohl, P.; Beneš, M.; Bojková, M.; Svoboda, P.; Konečný, M.; Falt, P.; Vaňásek, T.; Pešta, M.; Pešek, F.; Bouchner, L.; Koželuhová, J.; Novotný, A.; Bartůsková, L.; Špičák, J. Clinical monitoring: infliximab biosimilar CT-P13 in the treatment of Crohn’s disease and ulcerative colitis. Scand. J. Gastroenterol., 2016, 51(9), 1062-1068.
[25]
Park, S.H.; Kim, Y.H.; Lee, J.H.; Kwon, H.J.; Lee, S.H.; Park, D.I.; Kim, H.K.; Cheon, J.H.; Im, J.P.; Kim, Y.S.; Lee, S.Y.; Lee, S.J. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Expert Rev. Gastroenterol. Hepatol., 2015, 9(Suppl. 1), 35-44.
[26]
Kang, Y.S.; Moon, H.H.; Lee, S.E.; Lim, Y.J.; Kang, H.W. Clinical experience of the use of CT-P13, a Biosimilar to infliximab in patients with inflammatory bowel disease: A case series. Dig. Dis. Sci., 2015, 60(4), 951-956.
[27]
Jung, Y.S.; Park, D.I.; Kim, Y.H.; Lee, J.H.; Seo, P.J.; Cheon, J.H.; Kang, H.W.; Kim, J.W. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study. J. Gastroenterol. Hepatol., 2015, 30(12), 1705-1712.
[28]
Smits, L.J.; Derikx, L.A.; de Jong, D.J.; Boshuizen, R.S.; van Esch, A.A.; Drenth, J.P.; Hoentjen, F. (R) to the Biosimilar CT-P13 in inflammatory bowel disease patients: A prospective observational cohort study. J. Crohn’s Colitis, 2016, 10(11), 1287-1293.
[29]
Jahnsen, J.; Detlie, T.E.; Vatn, S.; Ricanek, P. Biosimilar infliximab (CT-P13) in the treatment of inflammatory bowel disease: A Norwegian observational study. Expert Rev. Gastroenterol. Hepatol., 2015, 9(Suppl. 1), 45-52.
[30]
Bálint, A.; Rutka, M.; Végh, Z.; Kürti, Z.; Gecse, K.B.; Banai, J.; Bene, L.; Gasztonyi, B.; Kristóf, T.; Lakatos, L.; Miheller, P.; Palatka, K.; Patai, Á.; Salamon, Á.; Szamosi, T.; Szepes, Z.; Tóth, G.T.; Vincze, Á.; Bor, R.; Milassin, Á.; Fábián, A.; Nagy, F.; Kolar, M.; Bortlik, M.; Duricova, D.; Hruba, V.; Lukas, M.; Mitrova, K.; Malickova, K.; Lukas, M.; Lakatos, P.L.; Molnár, T.; Farkas, K. Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort. Expert Opin. Drug Saf., 2017, 16(8), 885-890.
[31]
Fiorino, G.; Manetti, N.; Armuzzi, A.; Orlando, A.; Variola, A.; Bonovas, S.; Bossa, F.; Maconi, G. DʼIncà, R.; Lionetti, P.; Cantoro, L.; Fries, W.; Annunziata, M.L.; Costa, F.; Terpin, M.M.; Biancone, L.; Cortelezzi, C.C.; Amato, A.; Ardizzone, S.; Danese, S.; Guidi, L.; Rizzuto, G.; Massella, A.; Andriulli, A.; Massari, A.; Lorenzon, G.; Ghione, S.; Kohn, A.; Ventra, A.; Annese, V. The PROSIT-BIO Cohort: A prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar. Inflamm. Bowel Dis., 2017, 23(2), 233-243.
[32]
Sieczkowska, J.; Jarzębicka, D.; Banaszkiewicz, A.; Plocek, A.; Gawronska, A.; Toporowska-Kowalska, E.; Oracz, G.; Meglicka, M.; Kierkus, J. Preliminary observations. J. Crohn’s Colitis, 2016, 10(2), 127-132.
[33]
Danese, S.; Fiorino, G.; Michetti, P. Changes in biosimilar knowledge among European Crohn’s Colitis Organization (ECCO) members: A updated survey. J. Crohn’s Colitis, 2016, 10(11), 1362-1365.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
56
5
1
3